Mizuho has begun coverage of MannKind Corporation (MNKD, Financial) with an optimistic "Outperform" rating, assigning a target price of $12 per share. The firm's analysis indicates encouraging prospects for the ongoing adoption of Tyvaso DPI, despite the looming presence of new competition in the short term.
In addition to Tyvaso DPI's steady performance, Mizuho highlights the significant growth potential within MannKind's research and development initiatives. The upcoming results from the INHALE-1 study, which evaluates the potential expansion of Afrezza into the U.S. pediatric market, are seen as pivotal developments for the company. Furthermore, MannKind's advancements with MNKD-101 and MNKD-201 are expected to bring transformative changes in the near future.
Mizuho's analysis suggests that a successful outcome from these ventures could drive MannKind's stock price up towards $20. The firm's report underscores the substantial upside potential that these innovative projects might unlock for stakeholders.
